drugset / Trial / NCT02658279
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Active not recruiting
27 enrolled
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute · collabHuntsman Cancer Institute/ University of Utah · collabM.D. Anderson Cancer Center · collabMerck Sharp & Dohme LLC · collabUniversity of California, Los Angeles · collabUniversity of California, San Francisco · collabUniversity of Miami · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.
Timeline
- Start
- 2016-01-22
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |